Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW
APOPW was delisted on the 3rd of August, 2021.
2 hedge funds and large institutions have $58K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
13% less capital invested
Capital invested by funds: $67K → $58K (-$9K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.16K |
APOPW Hedge Fund Activity: Q3 2018 in Review
2 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q3 2018, worth a combined $58K — down 13% from $67K a quarter earlier.
Fund positioning in APOPW was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Susquehanna International Group, cutting an estimated $2.16K.
- 2 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $58K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q3 2018, down 13% quarter-over-quarter.
- 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q3 2018 and 0 closed out.
- The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs seller in Q3 2018 was Susquehanna International Group, an estimated $2.16K sold.
Based on aggregated 13F filings for Q3 2018.